Drugmakers plan Trump meeting next week amid health shakeups
Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s effort to work with the new administration. The details of the meeting are still...
View ArticleARPA-H chief is out as Trump administration cuts health agencies
Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical innovation, part of a broad series of ongoing changes being made by the new Trump ...
View ArticleJ&J to face pivotal hearing over its $8B talc settlement plan
Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases alleging the company’s talc products caused cancer. The controversial...
View ArticleNIH, CDC cuts expected as Trump shakeup hits healthcare
The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide cuts planned across several major health organizations and hints of more to...
View Article#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s...
Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson &...
View ArticleGSK follows Pfizer in meningococcal vaccine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer. Penmenvy was approved Friday for children and young adults ages 10 to 25. Chief...
View ArticleUpdates from Washington; A trio of Big Pharma deals; What do recent share...
Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week! Robert F. Kennedy Jr. is officially leading HHS as of Thursday ...
View ArticlePain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug approval last month, is targeting up to $150 million in a new funding round,...
View ArticleFDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi
The FDA approval of Romvimza in a rare cancer means Ono Pharmaceutical has a fight on its hands. The company must work to displace Daiichi Sankyo’s Turalio, and fortunately, Romvimza appears to have...
View ArticleExclusive: AI biotech Atomwise hires new CEO, raises $45M Series C
Atomwise spent most of its first 12 years talking up the potential of AI in making molecules. Now, the biotech startup is turning to an industry veteran with over 35 years of biotech experience to ...
View ArticleExclusive: Lithuanian biotech Atrandi Biosciences raises $25M Series A
A biotech based in Vilnius, Lithuania has won the backing of Lux Capital as the startup plots a US expansion in 2025. Lux led a recently-closed $25 million Series A round for Atrandi Biosciences,...
View ArticleAlgo’s topical pain treatment fails Phase 2 study with overperforming placebo
AlgoTherapeutix’s topical non-opioid drug has flunked a mid-stage trial in chemotherapy-induced pain due to a stronger-than-expected placebo arm, but the company is still determined to find a path...
View ArticleSubsense launches with $17M to build a noninvasive brain computer interface
Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding. Investments into neurotech have picked up over the past few years, most...
View ArticleBavarian Nordic wins FDA OK for chikungunya vaccine in challenge to Valneva
The FDA has approved Bavarian Nordic’s chikungunya vaccine for adolescents and adults, edging out Valneva’s vaccine, which is only approved in people at least 18 years old. Bavarian’s single-dose...
View ArticleHikma takes Amarin's 'skinny label' fight to the Supreme Court
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that helps bring more low-cost medications to...
View ArticleAfter research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet...
A month after Biogen signaled plans to shift its attention to "external opportunities," it delivered on that ambition. The drugmaker said Tuesday it's paying ...
View ArticleSepterna ends Phase 1 trial for hypoparathyroidism drug; Sanofi’s Merilog is...
Plus, news about Basilea, TME Pharma and Perceive Biotherapeutics: Septerna stops work on Phase 1: The newly public biotech ended a healthy volunteer trial for SEP-786, its hypoparathyroidism ...
View ArticleArcus touts early kidney cancer data as Gilead declines option
Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move forward into additional studies. At the same time, Gilead passed on its option to ...
View ArticleIn turnaround, Solid Bio reports promising initial data for Duchenne gene...
Solid Biosciences reported that three children with Duchenne muscular dystrophy who received its gene therapy saw high levels of a key muscle protein called microdystrophin in a clinical trial. The...
View ArticleWhat federal job cuts at HHS mean for health tech
Shortly after Robert F. Kennedy Jr. was confirmed as HHS secretary, the White House gave us a taste of what we might expect out of his time in office. First, the Trump administration issued an ...
View Article